Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-26 @ 12:31 AM
Study NCT ID:
NCT03602560
Status:
COMPLETED
Last Update Posted:
2022-08-02
First Post:
2018-07-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-01
Start Date Type:
ACTUAL
Primary Completion Date:
2020-02-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-02-16
Completion Date Type:
ACTUAL
First Submit Date:
2018-07-18
First Submit QC Date:
None
Study First Post Date:
2018-07-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-03-23
Results First Submit QC Date:
None
Results First Post Date:
2022-05-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-07
Last Update Post Date:
2022-08-02
Last Update Post Date Type:
ACTUAL